«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《现代肿瘤医学》[ISSN:1672-4992/CN:61-1415/R]

期数:

2023年13期

页码:

2486-2490

栏目:

论著（消化肿瘤）

出版日期:

2023-05-30

文章信息/Info

Title:

The expression of IL28RA in gastric cancer tissue and its relationship with clinical pathological features and prognosis

作者:

苏 晨; 张国山; 潘家超; 郑雅文

山东第一医科大学附属中心医院，山东 济南 250000

Author(s):

SU Chen; ZHANG Guoshan; PAN Jiachao; ZHENG Yawen

Central Hospital Affiliated to Shandong First Medical University,Shandong Jinan 250000,China.

关键词:

胃癌; IL28RA表达; 生存预后; CD8+T细胞

Keywords:

gastric cancer; expression of IL28RA; survival; CD8+T cells

分类号:

R735.2

DOI:

10.3969/j.issn.1672-4992.2023.13.021

文献标识码:

A

摘要:

目的：分析胃癌组织中IL-28RA的表达情况，以及与患者临床病理特征和预后的关系。方法：对胃癌组织芯片进行IL28RA、CD8及PD-L1免疫组化染色并判读。采用χ2检验分析IL28RA蛋白表达与胃癌患者临床病理特征的关系。采用Kaplan-Meier生存分析进行预后单因素分析，使用COX回归进行多因素分析。结果：共纳入94例胃癌患者，平均年龄62.4岁，其中男性55例，病理分级1-2级患者39例，肿瘤最大直径≤5 cm的54例，83%患者肿瘤发生于胃体及胃窦（78/94），III-IV期患者56例。我们发现癌与癌旁组织IL28RA表达无统计学差异。将IL28RA评分＞3及≤3分为高表达及低表达组，结果显示IL28RA表达在肿瘤TNM分期及PD-L1表达情况存在差异（P＜0.05），而与性别、年龄、肿瘤部位、大小等方面无差异。IL28RA高表达的胃癌患者预后更好（P=0.01）。多因素分析显示TNM分期、CD8+T细胞比例和IL28RA表达水平是影响胃癌预后的独立预测因素，HR分别为1.39（P=0.04）、0.55（P=0.04）和0.50（P=0.02）。TNM分期低、CD8+T细胞浸润比例高以及IL28RA表达高的患者，预后更好。联合三个因素同时对生存进行预测时，ROC曲线下面积可达0.727。结论：本研究发现胃癌患者中IL28RA高表达预示预后较好，提示IL28RA可能作为胃癌的一种预后预测因子。

Abstract:

Objective:To analyze the expression of IL28RA in gastric cancer tissue and its relationship with clinical pathological characteristics and prognosis of patients.Methods:Immunohistochemical staining of IL28RA,CD8 and PD-L1 was performed on gastric cancer tissue chip.χ2 test was used to analyze the relationship between IL28RA protein expression and clinicopathologic features of gastric cancer patients.Kaplan-Meier survival analysis for univariate analysis and COX regression for multivariate analysis were performed.Results:In 94 patients with gastric cancer,the average age was 62.4 years old,and the number of male patients was 55 cases,39 patients with pathological grade 1-2,54 cases with tumor diameter of 5 cm or less,56 cases with stage III-IV and 83% of patients with tumor occurred in the gastric body and antrum (78/94).There was no statistical difference in the expression of IL28RA between cancer and adjacent cancer.The patients were divided into high expression group and low expression group according to the IL28RA score >3 or ≤3.The results showed that the expression of IL28RA was different in tumor stage and PD-L1 expression (P＜0.05),but there was no difference with gender,age,tumor site and size.Gastric cancer patients with high expression of IL28RA had better prognosis (P=0.01).TNM stage,CD8+T cell proportion and IL28RA expression were independent prognostic factors of gastric cancer,and HR was 1.39 (P=0.04),0.55 (P=0.04) and 0.50 (P=0.02),respectively.Patients with low TNM staging,high percentage of CD8+T cell infiltration,and high expression of IL28RA had a better prognosis.When the three factors were combined to predict survival,the area under ROC curve reached 0.727.Conclusion:Our study showed that high expression of IL28RA in patients with gastric cancer predicted better prognosis,suggesting IL28RA as a potential prognostic factor of gastric cancer.

参考文献/References

［1］ STANIFER ML,GUO C,DOLDAN P,et al.Importance of type I and III interferons at respiratory and intestinal barrier surfaces［J］.Front Immunol,2020,11(1):608645.
［2］ MAJOR J,CROTTA S,LLORIAN M,et al.Type I and III interferons disrupt lung epithelial repair during recovery from viral infection［J］.Science,2020,369(6504):712-717.
［3］ SENCHUKOVA MA.Helicobacter pylori and gastric cancer progression［J］.Curr Microbiol,2022,79(12):383.
［4］ 郑雅文，赵华，魏枫，等.胃癌患者外周血干扰素水平的变化及其临床意义［J］.中国肿瘤生物治疗杂志,2013,20(06):725-728. ZHENG YW,ZHAO H,WEI F,et al.Changes and clinical significance of interferon levels in peripheral blood of gastric cancer patients ［J］.Chinese Journal of Cancer Biotherapy,2013,20(06):725-728.
［5］ VLACHIOTIS S,ANDREAKOS E.Lambda interferons in immunity and autoimmunity［J］.J Autoimmun,2019,104(1):102319.
［6］ BROGGI A,GRANUCCI F,ZANONI I.Type III interferons:Balancing tissue tolerance and resistance to pathogen invasion［J］.J Exp Med,2020,217(1):e20190295.
［7］ VITIELLO G,FERREIRA W,CORDEIRO DLV,et al.Antiviral responses in cancer:Boosting antitumor immunity through activation of interferon pathway in the tumor microenvironment［J］.Front Immunol,2021,12(1):782852.
［8］ LASFAR A,ZLOZA A,SILK AW,et al.Interferon lambda:Toward a dual role in cancer［J］.J Interferon Cytokine Res,2019,39(1):22-29.
［9］ ALPHONSE N,DICKENSON RE,ALREHAILI A,et al.Functions of IFNlambdas in anti-bacterial immunity at mucosal barriers［J］.Front Immunol,2022,13(1):857639.
［10］ STANIFER ML,KEE C,CORTESE M,et al.Critical role of type III interferon in controlling SARS-CoV-2 infection in human intestinal epithelial cells［J］.Cell Rep,2020,32(1):107863.
［11］ LIU L,QI Y,HUANG D,et al.Downregulated expression of IL28RA is involved in the pathogenesis of pancreatic ductal adenocarcinoma［J］.Int J Oncol,2021,59(2):55.
［12］ HUBERT M,GOBBINI E,COUILLAULT C,et al.IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer［J］.Sci Immunol,2020,5(46):eaav3942.
［13］ ZHANG Y,ZHAO ZX,GAO JP,et al.Tumor-infiltrating CD226(+)CD8(+) T cells are associated with postoperative prognosis and adjuvant chemotherapeutic benefits in gastric cancer patients［J/OL］.J Cancer Res Clin Oncol,2022［2022-09-15］.https://link.springer.com/article/10.1007/s00432-022-04346-x.
［14］ TONG G,ZHU M,CHEN Y,et al.Intratumoral CD8(+) T cells as a potential positive predictor of chemoimmunotherapy response in PD-L1-negative advanced gastric cancer patients:a retrospective cohort study［J］.J Gastrointest Oncol,2022,13(4):1668-1678.
［15］ WANG J,QIN D,TAO Z,et al.Identification of cuproptosis-related subtypes,construction of a prognosis model,and tumor microenvironment landscape in gastric cancer［J］.Front Immunol,2022,13(1):1056932.
［16］ YANG J,XU J,LING Z,et al.Prognostic effects of the gastric mucosal microbiota in gastric cancer［J/OL］.Cancer Sci,2022［2022-11-20］.https://onlinelibrary.wiley.com/doi/10.1111/cas.15661.
［17］ WONG PK,CHAN IN,YAN HM,et al.Deep learning based radiomics for gastrointestinal cancer diagnosis and treatment:A minireview［J］.World J Gastroenterol,2022,28(45):6363-6379.

备注/Memo

备注/Memo:

山东省自然科学基金资助项目（编号：ZR2021QH034）；山东省医药卫生科技发展计划项目（编号：202009030748）；山东省济南市科技计划（编号：201907122）

常用功能

更新日期/Last Update: 2023-05-31